Apollomics
ðŸ‡ðŸ‡°Hong Kong, China
- Country
- ðŸ‡ðŸ‡°Hong Kong, China
- Ownership
- -
- Employees
- 45
- Market Cap
- -
- Introduction
Apollomics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of oncology therapies to address unmet medical needs. The company was founded by Liang Yu Guo and Sanjeev Redkar in 2015 and is headquartered in Foster City, CA.
Evorpacept Shows Promise in HER2-Positive Gastric Cancer: Updated ASPEN-06 Data
• ALX Oncology's ASPEN-06 Phase 2 trial evaluates evorpacept, a CD47-blocker, in HER2-positive advanced gastric cancer patients who have been previously treated.
• Updated data from the ASPEN-06 trial were presented at the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI).
• The virtual event hosted by ALX Oncology on January 23, reviewed the ASPEN-06 data, focusing on evorpacept's potential in immuno-oncology.
• The ASPEN-06 trial is a phase 2/3 study of evorpacept in patients with HER2-overexpressing gastric/gastroesophageal cancer.
Apollomics' Uproleselan Fails Phase 3 Trial in Relapsed/Refractory AML
• Apollomics' Phase 3 trial of uproleselan in China did not meet its primary endpoint, showing no significant benefit in overall survival for patients with relapsed or refractory AML.
• The median overall survival in the uproleselan arm was 9.3 months, compared to 14.3 months in the chemotherapy-only arm, indicating a potential detriment with the addition of uproleselan.
• Due to the trial's failure and a previous unsuccessful global Phase 3 trial, Apollomics is discontinuing the uproleselan program, with remaining expenses expected to be under $500,000.
• Apollomics will focus on its lead program, vebreltinib (APL-101), a c-Met inhibitor currently in Phase 2 trials for non-small cell lung cancer and other advanced tumors.
© Copyright 2025. All Rights Reserved by MedPath